Literature DB >> 25362885

Highly efficient targeted chromosome deletions using CRISPR/Cas9.

Zuyong He1, Chris Proudfoot, Alan J Mileham, David G McLaren, C Bruce A Whitelaw, Simon G Lillico.   

Abstract

The CRISPR/Cas9 system has emerged as an intriguing new technology for genome engineering. It utilizes the bacterial endonuclease Cas9 which, when delivered to eukaryotic cells in conjunction with a user-specified small guide RNA (gRNA), cleaves the chromosomal DNA at the target site. Here we show that concurrent delivery of gRNAs designed to target two different sites in a human chromosome introduce DNA double-strand breaks in the chromosome and give rise to targeted deletions of the intervening genomic segment. Predetermined genomic DNA segments ranging from several-hundred base pairs to 1 Mbp can be precisely deleted at frequencies of 1-10%, with no apparent correlation between the size of the deleted fragment and the deletion frequency. The high efficiency of this technique holds promise for large genomic deletions that could be useful in generation of cell and animal models with engineered chromosomes.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  CRISPR/Cas9; HPRT; large genomic deletion

Mesh:

Substances:

Year:  2014        PMID: 25362885     DOI: 10.1002/bit.25490

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  25 in total

1.  Novel presenilin 1 and 2 double knock-out cell line for in vitro validation of PSEN1 and PSEN2 mutations.

Authors:  Anna A Pimenova; Alison M Goate
Journal:  Neurobiol Dis       Date:  2020-02-04       Impact factor: 5.996

2.  Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia.

Authors:  D L Ouellet; K Cherif; J Rousseau; J P Tremblay
Journal:  Gene Ther       Date:  2016-12-26       Impact factor: 5.250

3.  Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis.

Authors:  Jayashree A Chandrasekharan; Xiao M Huang; Alexander C Hwang; Neelam Sharma-Walia
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

4.  A versatile reporter system for CRISPR-mediated chromosomal rearrangements.

Authors:  Yingxiang Li; Angela I Park; Haiwei Mou; Cansu Colpan; Aizhan Bizhanova; Elliot Akama-Garren; Nik Joshi; Eric A Hendrickson; David Feldser; Hao Yin; Daniel G Anderson; Tyler Jacks; Zhiping Weng; Wen Xue
Journal:  Genome Biol       Date:  2015-05-28       Impact factor: 13.583

Review 5.  CRISPR-Cas9-mediated genome editing and guide RNA design.

Authors:  Michael V Wiles; Wenning Qin; Albert W Cheng; Haoyi Wang
Journal:  Mamm Genome       Date:  2015-05-20       Impact factor: 2.957

6.  CRISPR-PCS: a powerful new approach to inducing multiple chromosome splitting in Saccharomyces cerevisiae.

Authors:  Yu Sasano; Koki Nagasawa; Saeed Kaboli; Minetaka Sugiyama; Satoshi Harashima
Journal:  Sci Rep       Date:  2016-08-17       Impact factor: 4.379

7.  Comparison of CRISPR/Cas9 and TALENs on editing an integrated EGFP gene in the genome of HEK293FT cells.

Authors:  Zuyong He; Chris Proudfoot; C Bruce A Whitelaw; Simon G Lillico
Journal:  Springerplus       Date:  2016-06-21

8.  Efficient Generation of Myostatin Knock-Out Sheep Using CRISPR/Cas9 Technology and Microinjection into Zygotes.

Authors:  M Crispo; A P Mulet; L Tesson; N Barrera; F Cuadro; P C dos Santos-Neto; T H Nguyen; A Crénéguy; L Brusselle; I Anegón; A Menchaca
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

Review 9.  Engineering large animal models of human disease.

Authors:  C Bruce A Whitelaw; Timothy P Sheets; Simon G Lillico; Bhanu P Telugu
Journal:  J Pathol       Date:  2015-11-28       Impact factor: 7.996

Review 10.  Gene targeting, genome editing: from Dolly to editors.

Authors:  Wenfang Tan; Chris Proudfoot; Simon G Lillico; C Bruce A Whitelaw
Journal:  Transgenic Res       Date:  2016-02-03       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.